



Dosing and Administration Guide



Bonnie, Mycapssa patient

Visit [chiesitotalcare.com](https://www.chiesitotalcare.com)
or call 1-833-346-2277
We're ready to help!

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

Mycapssa (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



Make Your Move: Reach Maintenance in Under 2 Months

Mycapssa may be initiated as soon as the patient shows a response and is able to tolerate treatment with octreotide or lanreotide.

Example of treatment schedule:



*In patients who respond to and tolerate treatment with iSSA.
†Based on the evaluation of IGF-I, signs, and symptoms.
‡Once the maintenance dosage is achieved, monitor IGF-I, signs, and symptoms periodically.

Each wallet of Mycapssa comes with 28 capsules.
Each Mycapssa capsule is 20 mg.



IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS


The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

Rapid and Personalized Titration With Mycapssa®

Evaluate IGF-I, signs, and symptoms every 2 weeks during the dose titration period. Adjust dose if needed.

Example titration schedule:



In the OPTIMAL trial: The majority of Mycapssa-treated patients titrated to the 80-mg dose. Adverse events were not dose related.

Once the maintenance dosage of Mycapssa is achieved, monitor IGF-I levels and acromegaly signs and symptoms periodically.

Twice-Daily Dosing Treats Acromegaly All Day, Every Day

Mycapssa Offers a Flexible Dosing Schedule

- First and second doses do not need to be taken exactly 12 hours apart or at the same time each day
- Mycapssa should be taken 1 hour before or 2 hours after meals

Take Mycapssa on an empty stomach twice daily with a glass of water



Once opened, Mycapssa wallets can be stored at room temperature for 30 days, and do not need to be refrigerated.*

*Opened wallets may be stored at room temperature (68° to 77°F) for up to 1 month



If you have questions, visit chiesitotalcare.com
or call 1-833-346-2277 – we're ready to help!

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

Mycapssa (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of Mycapssa. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS

Mycapssa can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B₁₂ levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with Mycapssa and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.

ADVERSE REACTIONS

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The following drugs require monitoring and possible dose adjustment when used with Mycapssa: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking Mycapssa.

Patients taking proton pump inhibitors, H₂-receptor antagonists, or antacids concomitantly with Mycapssa may require increased dosages of Mycapssa.

PREGNANCY

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information and accompanying full Prescribing Information.

For more information, visit mycapssa.com.

Chiesi Total CareSM Program offered through PANTHERSM Rare Pharmacy.

©Chiesi USA, Inc. 2025. All rights reserved.

Mycapssa[®] is a registered trademark owned by the Chiesi Group.

PANTHERSM Rare PharmacySM is a registered service mark of PANTHERSM Specialty LLC.

Chiesi Total CareSM is a service mark owned by Chiesi Farmaceutici S.p.A.

PP-MC-0004 V3.0